← Back to Home

Six-patient trial shows signs of retinal protection: AI analysis helps assess nonviral gene therapy

PST-611 aims to slow retinal damage caused by geographic atrophy by regulating iron balance. Images from six patients show preliminary changes, but post hoc analysis and short-term follow-up are not yet sufficient to prove that the therapy can preserve vision.

By SURL BioNews

Reading and recognizing faces both depend on clear central vision. Once dry age-related macular degeneration progresses to geographic atrophy, these everyday abilities may be impaired as retinal cells are lost. On October 7, PulseSight Therapeutics announced an imaging analysis from a six-patient trial, reporting that some indicators of retinal damage worsened more slowly after treatment with the investigational gene therapy PST-611. This provides a research lead for protecting remaining cells, but confirming benefits for patients remains some way off.

PST-611 uses nonviral gene delivery to carry DNA encoding human transferrin. According to the company's technical description, an electrotransfection system delivers the DNA into ciliary muscle cells, enabling them to produce a therapeutic protein that can reach the retina. The idea is to regulate iron balance within the eye: excess free iron may promote oxidative stress and lipid peroxidation, contributing to a cell death process called “ferroptosis.” Whether increasing transferrin can effectively block this damage in humans is precisely what the therapy needs to demonstrate.

This first-in-human Phase 1 trial primarily assessed safety and tolerability. Six patients were divided into two ascending-dose groups, each receiving a single administration and undergoing four months of follow-up. The new findings come from an exploratory analysis conducted after the trial was completed and presented on October 2 at the EURETINA annual meeting in Vienna. The RetinAI research team used the Discovery platform and AI models to compare optical coherence tomography (OCT) scans before and after treatment, quantifying four structural indicators of retinal cell loss.

According to data released by PulseSight and reported by the ophthalmology publication Retinal Physician, five of the six patients showed early signals of structural change. Across all patients, the average rates of worsening for the indicators during the four months after treatment were 35% to 52% lower than before treatment. Specifically, the rate of expansion of retinal pigment epithelium loss decreased by 40%, the rate of expansion of photoreceptor ellipsoid zone loss decreased by 35%, and the rate of thickness loss in that zone decreased by 52%. These percentages describe the pace of damage progression; they cannot be interpreted as the magnitude of vision improvement, nor do they indicate that lost cells were restored.

AI served here as an imaging measurement tool, converting changes in retinal structure across follow-up visits into comparable numerical values. However, an open-label safety trial involving six patients and a post hoc comparison before and after treatment cannot rule out differences in the natural course of disease and measurement variability in the way a randomized controlled study can. The company also mentioned spontaneous patient reports of improvements in everyday vision, but these cannot replace standardized tests of visual function. Four months of observation is also insufficient to establish long-term efficacy and safety.

The regulatory status of the imaging tools also requires a clear distinction. RetinAI says the Discovery platform has received US FDA clearance for clinical use, but its AI modules for retinal biomarkers, segmentation, and quantification remain restricted to research use in the United States. Clearance of the platform does not mean that this analysis has been accepted for determining the efficacy of PST-611. Whether the imaging indicators can reliably reflect preservation of visual function still needs to be confirmed in subsequent studies.

These analyses have already been used to plan the next stage of trials. PulseSight expects to launch an open-label, repeat-dose Phase 2a trial in the second half of 2026, enrolling up to 24 participants and administering up to three doses over 12 months, with results expected in 2028. RetinAI will continue to support data collection, centralized image management, and exploratory analysis. Longer follow-up can assess whether the signals persist, while stronger comparative evidence is still needed to clarify the therapy's actual contribution to vision.

References

  1. PulseSight Therapeutics
  2. RetinAI
  3. Retinal Physician